Morgan Stanley
TOVX icon

Morgan Stanley’s Theriva Biologics TOVX Stock Holding History

Morgan Stanley’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.62K Sell
23,602
-176,398
-88% -$34.8K ﹤0.01% 7160
2025
Q4 		$42.1K Buy
+200,000
New +$59.1K ﹤0.01% 6489
2024
Q4 		– Sell
-20,200
Closed -$27.9K – 8088
2024
Q3 		$27.9K Buy
20,200
+20,199
+2,019,900% +$98.5K ﹤0.01% 6396
2024
Q2 		$4 Hold
1
– – ﹤0.01% 7815
2024
Q1 		$7 Sell
1
-40
-98% -$468 ﹤0.01% 7782
2023
Q4 		$444 Buy
+41
New +$505 ﹤0.01% 7292
2023
Q3 		– Hold
0
– – – 7578
2023
Q2 		– Hold
0
– – – 7598
2023
Q1 		– Sell
-27
Closed -$560 – 7681
2022
Q4 		$305 Buy
27
+15
+125% +$272 ﹤0.01% 7605
2022
Q3 		$0 Hold
12
– – ﹤0.01% 7873
2022
Q2 		$1K Buy
12
+1
+9% +$57 ﹤0.01% 7706
2022
Q1 		$1K Sell
11
-73
-87% -$4.97K ﹤0.01% 7872
2021
Q4 		$6K Hold
84
– – ﹤0.01% 7611
2021
Q3 		$10K Buy
84
+83
+8,300% +$10.3K ﹤0.01% 7332
2021
Q2 		$0 Hold
1
– – ﹤0.01% 7802
2021
Q1 		$0 Hold
1
– – ﹤0.01% 7564
2020
Q4 		$0 Hold
1
– – ﹤0.01% 7112
2020
Q3 		$0 Hold
1
– – ﹤0.01% 6826
2020
Q2 		$0 Sell
1
-1
-50% -$95 ﹤0.01% 6722
2020
Q1 		$0 Buy
2
+1
+100% +$114 ﹤0.01% 6706
2019
Q4 		$0 Hold
1
– – ﹤0.01% 6762
2019
Q3 		$0 Hold
1
– – ﹤0.01% 6758
2019
Q2 		$0 Sell
1
-1
-50% -$144 ﹤0.01% 6748
2019
Q1 		$0 Hold
2
– – ﹤0.01% 6706
2018
Q4 		$0 Hold
2
– – ﹤0.01% 6736
2018
Q3 		$1K Sell
2
-2
-50% -$2.21K ﹤0.01% 6652
2018
Q2 		$9K Buy
4
+1
+33% +$2.3K ﹤0.01% 6333
2018
Q1 		$7K Buy
3
+1
+50% +$3.8K ﹤0.01% 6342
2017
Q4 		$10K Sell
2
-2
-50% -$12.5K ﹤0.01% 6219
2017
Q3 		$35K Sell
4
-26
-87% -$150K ﹤0.01% 5882
2017
Q2 		$151K Buy
30
+11
+58% +$54.8K ﹤0.01% 5469
2017
Q1 		$106K Sell
19
-26
-58% -$181K ﹤0.01% 5578
2016
Q4 		$300K Buy
45
+31
+221% +$318K ﹤0.01% 5186
2016
Q3 		$215K Buy
14
+1
+8% +$15K ﹤0.01% 4984
2016
Q2 		$197K Sell
13
-4
-24% -$75.3K ﹤0.01% 4945
2016
Q1 		$349K Buy
17
+3
+21% +$45.1K ﹤0.01% 4640
2015
Q4 		$279K Sell
14
-21
-60% -$444K ﹤0.01% 4903
2015
Q3 		$701K Buy
35
+27
+338% +$664K ﹤0.01% 4381
2015
Q2 		$194K Hold
8
– – ﹤0.01% 5258
2015
Q1 		$151K Buy
8
+4
+100% +$71.4K ﹤0.01% 5337
2014
Q4 		$51K Hold
4
– – ﹤0.01% 5814
2014
Q3 		$57K Hold
4
– – ﹤0.01% 5687
2014
Q2 		$55K Sell
4
-35
-90% -$555K ﹤0.01% 5736
2014
Q1 		$884K Buy
39
+36
+1,200% +$745K ﹤0.01% 4104
2013
Q4 		$41K Sell
3
-2
-40% -$25.2K ﹤0.01% 5668
2013
Q3 		$79K Hold
5
– – ﹤0.01% 5140
2013
Q2 		$81K Buy
+5
New +$68.4K ﹤0.01% 5121

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Morgan Stanley's TOVX Position: Q1 2026 in Review

Morgan Stanley reduced its Theriva Biologics (TOVX) stake by 88% in Q1 2026, selling an estimated $34.8K and leaving 23,602 shares worth $4.62K. The position accounts for ﹤0.01% of the portfolio, ranked #7160.

Morgan Stanley first reported a position in TOVX in Q2 2013 and has held it in 45 quarters since. The position peaked at $884K in Q1 2014. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • Morgan Stanley held 23,602 shares of Theriva Biologics worth $4.62K as of Q1 2026.
  • Morgan Stanley sold 176,398 Theriva Biologics shares in Q1 2026, an estimated $34.8K.
  • Theriva Biologics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7160 holding.
  • Morgan Stanley first reported a position in Theriva Biologics in Q2 2013 and has held it in 45 quarters since.
  • Morgan Stanley's Theriva Biologics position peaked at $884K in Q1 2014.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.